title: A high throughput in vitro mrp2 assay to predict in vivo biliary excretion.
abstract: Prediction of biliary excretion is a challenge for drug discovery scientists due to the lack of in vitro assays. This study explores the possibility of establishing a simple assay to predict in vivo biliary excretion via the mrp2 transport system.        In vitro mrp2 activity was determined by measuring the ATP-dependent uptake of 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) in canalicular plasma membrane vesicles (cLPM) from rat livers. The CDCF uptake was time- and concentration-dependent (K(m) of 2.2 ± 0.3 µM and V(max) of 115 ± 26 pmol/mg/min) and strongly inhibited by the mrp2 inhibitors, benzbromarone, MK-571, and cyclosporine A, with IC(50) values ≤ 1.1 µM.        Low inhibition of CDCF uptake by taurocholate (BSEP inhibitor; 57 µM) and digoxin (P-gp inhibitor; 101 µM) demonstrated assay specificity towards mrp2.        A highly significant correlation (r(2) = 0.959) between the in vitro IC(50) values from the described mrp2 assay and in vivo biliary excretion in rats was observed using 10 literature compounds.        This study demonstrated, for the first time, that a high throughput assay could be established with the capability of predicting biliary excretion in the rat using CDCF as a substrate.
authors.affiliation: Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, Québec, Canada.
authors.forename: Federico
authors.initials: F
authors.lastname: Colombo
authors.forename: Catherine
authors.initials: C
authors.lastname: Armstrong
authors.forename: Jianmin
authors.initials: J
authors.lastname: Duan
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rioux
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D001553:Benzbromarone / Q000737:chemistry / Q000494:pharmacology; D001648:Bile Canaliculi; D001659:Biliary Tract / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D016572:Cyclosporine / Q000737:chemistry / Q000494:pharmacology; D004077:Digoxin / Q000737:chemistry / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004347:Drug Interactions; D005452:Fluoresceins / Q000032:analysis / Q000493:pharmacokinetics; D057166:High-Throughput Screening Assays / Q000379:methods*; D008657:Metabolic Clearance Rate; D011422:Propionates / Q000737:chemistry / Q000494:pharmacology; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D013656:Taurocholic Acid / Q000737:chemistry / Q000494:pharmacology; D022161:Transport Vesicles
chemical_list: D018528:ATP-Binding Cassette Transporters; C423013:Abcc2 protein, rat; D005452:Fluoresceins; D011422:Propionates; D011804:Quinolines; C053897:5(6)-carboxy-2',7'-dichlorofluorescein; D001553:Benzbromarone; D013656:Taurocholic Acid; C059141:verlukast; D004077:Digoxin; D016572:Cyclosporine